Title : Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial.

Pub. Date : 2017 Mar 1

PMID : 27831502

1 Functional Relationships(s)
Compound Name
Protein Name
1 In HER2+/HR+ tumors, the pCR rate was 52.9% (49.7% Pac, 56.4% nab-Pac). nab erb-b2 receptor tyrosine kinase 2 Homo sapiens